, 8:A19,
Open Access This content is freely available online to anyone, anywhere at any time.
Date: 02 Nov 2012

Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients